Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: A case-control study from Denmark

British Journal of Dermatology

Volumn 165, Issue 4, 2011, Pages 828-836

  Elmholdt, T R ^a,b   Pedersen, M ^a,c   Jorgensen B ^b   Sondergaard K ^b   Jensen, J D ^b   Ramsing, M ^d   Olesen, A B ^b  

^a Institute of Clinical Medicine   (Denmark)

^b Department of Dermatology ^*  (Denmark)

^c MR Research Centre   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; MACROCYCLIC COMPOUND; PHOSPHATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DENMARK; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RISK ASSESSMENT; RISK FACTOR; SKIN EXAMINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PHOSPHORIC ACID ESTERS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RISK FACTORS; YOUNG ADULT;

EID: 80053547338     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10465.x     Document Type: Article

References (47)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
2. Saenz A, Mandal R, Kradin R, Hedley-Whyte ET,. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006; 449: 389-91. (Pubitemid 44367984)
3. Koreishi AF, Nazarian RM, Saenz AJ, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009; 133: 1943-8.
4. Edgar E, Woltjer R, Whitham R, et al. Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation. Neuromuscul Disord 2010; 20: 411-13.
5. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 238-49. (Pubitemid 43185214)
6. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009; 250: 371-7.
7. Moreno-Romero JA, Segura S, Mascaro JM Jr, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007; 157: 783-7. (Pubitemid 47389867)
8. Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73: 1413-18. (Pubitemid 351770496)
9. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008; 190: 736-41. (Pubitemid 351304519)
10. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
11. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273-80.
12. Kay J,. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med 2008; 75: 112, 114, 117.
13. Marckmann P,. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol 2008; 66: 187-90.
14. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007; 57: 105-11. (Pubitemid 46899273)
15. Kay J,. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008; 67 (Suppl. 3): iii66-9.
16. Deo A, Fogel M, Cowper SE,. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-7.
17. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62. (Pubitemid 44300951)
18. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
19. Czirjak L, Nagy Z, Aringer M, et al. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66: 966-9. (Pubitemid 46999803)
20. Cowper SE, Rabach M, Girardi M,. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 191-9.
21. Marckmann P, Skov L,. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 2009; 47: 833-40, vi.
22. Rydahl C, Thomsen HS, Marckmann P,. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-4.
23. Todd DJ, Kagan A, Chibnik LB, Kay J,. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56: 3433-41. (Pubitemid 47585439)
24. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2010; 73: 357-9.
25. Zou Z, Ma L, Li H,. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009; 30: 1309-12.
26. Bryant BJ, Im K, Broome DR,. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009; 64: 706-13.
27. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-57. (Pubitemid 46579705)
28. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248: 807-16.
29. Hubbard V, Davenport A, Jarmulowicz M, Rustin M,. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003; 148: 563-8. (Pubitemid 36461338)
30. Singh M, Davenport A, Clatworthy I, et al. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 2008; 158: 1358-62. (Pubitemid 351692857)
31. Weenig RH, Gibson LE, el-Azhary R,. The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. Semin Cutan Med Surg 2007; 26: 163-7. (Pubitemid 350216508)
32. Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L,. Dermatologic conditions seen in end-stage renal disease. Semin Dial 2009; 22: 45-55.
33. Kim RH, Ma L, Hayat SQ, Ahmed MM,. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in 2 patients with end-stage renal disease on hemodialysis. J Clin Rheumatol 2006; 12: 134-6. (Pubitemid 44314973)
34. Elmholdt TR, Jørgensen B, Ramsing M, et al. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010; 3: 285-7.
35. Wollanka H, Weidenmaier W, Giersig C,. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009; 24: 3882-4.
36. Bangsgaard N, Marckmann P, Rossen K, Skov L,. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145: 183-7.
37. Girardi M,. Nephrogenic systemic fibrosis: a dermatologist's perspective. J Am Coll Radiol 2008; 5: 40-4.
38. Deng A, Martin DB, Spillane A, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010; 37: 204-10.
39. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009; 253: 81-9.
40. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174-8. (Pubitemid 350202540)
41. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31: 440-6.
42. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-5. (Pubitemid 46780577)
43. Grobner T, Prischl FC,. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21: 135-9.
44. Peak AS, Sheller A,. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother 2007; 41: 1481-5. (Pubitemid 47311368)
45. Bahrami S, Raman SS, Sauk S, et al. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009; 33: 819-23.
46. Lee CU, Wood CM, Hesley GK, et al. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol 2009; 145: 1095-102.
47. Becker S, Walter S, Witzke O, et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol 2010; 73: 426-30.